When is it worth reducing overuse of health care services? The example of prescribing expensive antihypertensives;Wann lohnt es, eine medizinische überversorgung abzubauen? Das beispiel der verschreibung teurer antihypertonika

Medizinische Klinik

Volumn 100, Issue 9, 2005, Pages 535-541

  Gandjour, Afschin ^a   Lauterbach, Karl Wilhelm ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antihypertensive agents; Efficiency; Quality improvement

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; GERMANY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; MATHEMATICAL MODEL; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; QUALITY CONTROL;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; COST SAVINGS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEALTH RESOURCES; HEALTH SERVICES; HEALTH SERVICES MISUSE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, THEORETICAL; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PREVALENCE; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 25444498865     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-005-1073-6     Document Type: Article

References (25)

1. Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen. Gutachten 200/2001, Bd III: Über-, Unter- und Fehlversorgung. Bonn: Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen, 2001.
2. Gandjour A, Lauterbach KW. Zur Wirtschaftlichkeit von Qualitätsverbesserungsmaßnahmen im Gesundheitswesen. Med Klin 2002;8:499-502.
3. Gandjour A, Lauterbach KW. When is it worth introducing a quality improvement program? A mathematical model. Med Decis Making 2003;23:518-25.
4. Gandjour A, Lauterbach KW. Wann lohnt sich der Abbau medizinischer Unter- und Überversorgung? Das Beispiel der Behandlung akuter Depressionen. Psychiatr Prax 2004;31:157-62.
5. Thefeld W. Verbreitung der Herz-Kreislauf-Risikofaktoren Hypercholesterinämie, Übergewicht, Hypertonie und Rauchen in der Bevölkerung. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2000;43:415-23.
6. Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004;22:479-86.
7. Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? CMAJ 1999;161:25-32.
8. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
10. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44.
11. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J Hypertens 2003;21:1055-76.
12. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003;362:1527-35.
13. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
14. Gasse C, Hense HW, Stieber J, et al. Factors associated with differences in antihypertensive drug treatment: results from the MONICA Augsburg Population Surveys 1989/90 and 1994/95. Soz Präventivmed 2002;47:128-42.
15. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75.
16. Zentralinstitut für die kassenärztliche Versorgung. Patienten-Arzt-Panel (ADT-Panel) zur Morbiditäts-analyse. Köln-Berlin: ZI, 2001.
17. Fretheim A, Aaserud M, Oxman AD. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Serv Res 2003;3:18.
18. Berings D, Blondeel L, Habraken H. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. Eur J Clin Pharmacol 1994;46:501-5.
19. Marton KI, Tul V, Sox HC Jr. Modifying test-ordering behavior in the outpatient medical clinic. A controlled trial of two educational interventions. Arch Intern Med 1985;145:816-21.
20. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-iv, 1-72.
21. Bognar Z, König M, Vossmerbäumer U. Arzneimittelkostenmanagement durch Pharmakotherapie: Servicepartner Krankenkasse, in: Salfeld R, Wettke J, Hrsg. Die Zukunft des deutschen Gesundheitswesens: Perspektiven und Konzepte. Berlin: Springer, 2001:141-56.
22. Oßwald H, Mühlbauer B. Diuretika. In: Schwabe U, Paffrath D, Hrsg. Arzneiverordnungsreport 2003. Berlin-Heidelberg: Springer, 2004;464-79.
23. Kassenärztliche Bundesvereinigung. Einheitlicher Bewertungsmaßstab. Köln: Deutscher Ärzte-Verlag, 2003.
24. Rote Liste® Service GmbH. Rote Liste®. Aulendorf: Editio Cantor, 2004.
25. Mason J, Freemantle N, Nazareth I, et al. When is it cost-effective to change the behavior of health professionals? JAMA 2001;286:2988-92.